1-16 of 16
James E. Herndon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage

James Isaacs, Aaron C. Tan, Brent A. Hanks, Xiaofei Wang, Kouros Owzar, James E. Herndon, II, Scott J. Antonia, Steven Piantadosi, Mustafa Khasraw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 13–22.
https://doi.org/10.1158/1078-0432.CCR-21-1593
Published: 05 January 2022
View article titled, Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
Open the PDF for Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage in another window
Journal Articles

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

Kristen A. Batich, Duane A. Mitchell, Patrick Healy, James E. Herndon, II, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5297–5303.
https://doi.org/10.1158/1078-0432.CCR-20-1082
Published: 15 October 2020
View article titled, Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
Open the PDF for Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma in another window
Journal Articles

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts

Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. Herndon, II, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson, Luis Sanchez-Perez
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 358–368.
https://doi.org/10.1158/1078-0432.CCR-18-1211
Published: 03 January 2019
View article titled, Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts
Open the PDF for Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts in another window
Journal Articles

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Patrick C. Gedeon, Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, Robert J. Schmittling, Scott E. Szafranski, Xiuyu Cui, Patrick N. Healy, James E. Herndon, II, Roger E. McLendon, Stephen T. Keir, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Darell D. Bigner, John H. Sampson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3611–3631.
https://doi.org/10.1158/1078-0432.CCR-17-0126
Published: 31 July 2018
View article titled, A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Open the PDF for A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma in another window
Includes: Supplementary data
Journal Articles

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

Kristen A. Batich, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, Weihua Xie, James E. Herndon, II, Patrick Healy, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell Bigner, Gordana Vlahovic, Duane A. Mitchell, John H. Sampson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1898–1909.
https://doi.org/10.1158/1078-0432.CCR-16-2057
Published: 13 April 2017
View article titled, Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Open the PDF for Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination in another window
Includes: Supplementary data
Journal Articles

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

John H. Sampson, Bryan D. Choi, Luis Sanchez-Perez, Carter M. Suryadevara, David J. Snyder, Catherine T. Flores, Robert J. Schmittling, Smita K. Nair, Elizabeth A. Reap, Pamela K. Norberg, James E. Herndon, II, Chien-Tsun Kuan, Richard A. Morgan, Steven A. Rosenberg, Laura A. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 972–984.
https://doi.org/10.1158/1078-0432.CCR-13-0709
Published: 16 February 2014
View article titled, EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
Open the PDF for EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss in another window
Journal Articles

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

James J. Vredenburgh, Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, II, Jennifer Marcello, John P. Kirkpatrick, John H. Sampson, Leighann Bailey, Stevie Threatt, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4119–4124.
https://doi.org/10.1158/1078-0432.CCR-11-0120
Published: 15 June 2011
View article titled, The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma
Open the PDF for The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma in another window
Journal Articles

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

Jennifer A. Quinn, Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Allan H. Friedman, Darell D. Bigner, John H. Sampson, Roger E. McLendon, James E. Herndon, II, Stevie Threatt, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 1064–1068.
https://doi.org/10.1158/1078-0432.CCR-08-2130
Published: 02 February 2009
View article titled, Phase II Trial of Gliadel plus <em>O</em><sup>6</sup>-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme
Open the PDF for Phase II Trial of Gliadel plus <em>O</em><sup>6</sup>-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme in another window
Journal Articles

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Annick Desjardins, David A. Reardon, James E. Herndon, II, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7068–7073.
https://doi.org/10.1158/1078-0432.CCR-08-0260
Published: 03 November 2008
View article titled, Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Open the PDF for Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

James J. Vredenburgh, Annick Desjardins, James E. Herndon, II, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, Melissa Wagner, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1253–1259.
https://doi.org/10.1158/1078-0432.CCR-06-2309
Published: 22 February 2007
View article titled, Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Open the PDF for Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma in another window
Journal Articles

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

Chien-Tsun Kuan, Kenji Wakiya, Jeannette M. Dowell, James E. Herndon, II, David A. Reardon, Michael W. Graner, Gregory J. Riggins, Carol J. Wikstrand, Darell D. Bigner
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 1970–1982.
https://doi.org/10.1158/1078-0432.CCR-05-2797
Published: 11 April 2006
View article titled, Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme
Open the PDF for Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme in another window
Journal Articles

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, James E. Herndon, II, Jeannette M. Dowell, Roger E. McLendon, James M. Provenzale, John H. Sampson, Robert P. Smith, Alan J. Swaisland, Judith S. Ochs, Peggy Lyons, Sandy Tourt-Uhlig, Darell D. Bigner, Henry S. Friedman, Jeremy N. Rich
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 860–868.
https://doi.org/10.1158/1078-0432.CCR-05-2215
Published: 07 February 2006
View article titled, Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Open the PDF for Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma in another window
Journal Articles

High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

Mary-Beth Moore Joshi, Yoshinori Shirota, Kathleen D. Danenberg, Debbi H. Conlon, Dennis S. Salonga, James E. Herndon, II, Peter V. Danenberg, David H. Harpole, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2215–2221.
https://doi.org/10.1158/1078-0432.CCR-04-1387
Published: 23 March 2005
View article titled, High Gene Expression of <em>TS1</em>, <em>GSTP1</em>, and <em>ERCC1</em> Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer
Open the PDF for High Gene Expression of <em>TS1</em>, <em>GSTP1</em>, and <em>ERCC1</em> Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer in another window
Journal Articles

Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B

Ramaswamy Govindan, Robert A. Kratzke, James E. Herndon, II, Gloria A. Niehans, Robin Vollmer, Dorothy Watson, Mark R. Green, Hedy L. Kindler, on behalf of the Cancer and Leukemia Group B (CALGB 30101)
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2300–2304.
https://doi.org/10.1158/1078-0432.CCR-04-1940
Published: 23 March 2005
View article titled, Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
Open the PDF for Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B in another window
Journal Articles

Immunohistochemical Detection of Occult Lymph Node Metastases in Non-Small Cell Lung Cancer: Anatomical Pathology Results from Cancer and Leukemia Group B Trial 9761

Robin T. Vollmer, James E. Herndon, II, Jonathan D’Cunha, Naif Z. Abraham, Joette Solberg, Mitra Fatourechi, Ann Maruska, Jeffrey A. Kern, Mark R. Green, Robert A. Kratzke, Michael A. Maddaus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5630–5635.
Published: 03 December 2003
View article titled, Immunohistochemical Detection of Occult Lymph Node Metastases in Non-Small Cell Lung Cancer: <subtitle>Anatomical Pathology Results from Cancer and Leukemia Group B Trial 9761</subtitle>
Open the PDF for Immunohistochemical Detection of Occult Lymph Node Metastases in Non-Small Cell Lung Cancer: <subtitle>Anatomical Pathology Results from Cancer and Leukemia Group B Trial 9761</subtitle> in another window
Journal Articles

The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer

David H. Harpole, Jr., Mary-Beth Moore, James E. Herndon, II, Thomas Aloia, Thomas A. D’Amico, Thomas Sporn, Allyson Parr, Ilona Linoila, Carmen Allegra
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 562–569.
Published: 01 March 2001
View article titled, The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer
Open the PDF for The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer in another window